Patents by Inventor Jonathan Penfield

Jonathan Penfield has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250207171
    Abstract: The present invention provides engineered ketoreductase and phosphite dehydrogenase enzymes having improved properties as compared to a naturally occurring wild-type ketoreductase and phosphite dehydrogenase enzymes, as well as polynucleotides encoding the engineered ketoreductase and phosphite dehydrogenase enzymes, host cells capable of expressing the engineered ketoreductase and phosphite dehydrogenase enzymes, and methods of using the engineered ketoreductase and phosphite dehydrogenase enzymes to synthesize a chiral catalyst used in the synthesis of antiviral compounds, such as nucleoside inhibitors. The present invention further provides methods of using the engineered enzymes to deracemize a chiral alcohol in a one-pot, multi-enzyme system.
    Type: Application
    Filed: March 14, 2025
    Publication date: June 26, 2025
    Inventors: Jeffrey C. Moore, Jack Liang, Jonathan Penfield, Jovana Nazor, Nikki Dellas, Vesna Mitchell, Da Duan, Iman Farasat, Agustina Rodriguez-Granillo, Grant Murphy, Nicholas Marshall
  • Patent number: 12252723
    Abstract: The present invention provides engineered ketoreductase and phosphite dehydrogenase enzymes having improved properties as compared to a naturally occurring wild-type ketoreductase and phosphite dehydrogenase enzymes, as well as polynucleotides encoding the engineered ketoreductase and phosphite dehydrogenase enzymes, host cells capable of expressing the engineered ketoreductase and phosphite dehydrogenase enzymes, and methods of using the engineered ketoreductase and phosphite dehydrogenase enzymes to synthesize a chiral catalyst used in the synthesis of antiviral compounds, such as nucleoside inhibitors. The present invention further provides methods of using the engineered enzymes to deracemize a chiral alcohol in a one-pot, multi-enzyme system.
    Type: Grant
    Filed: July 14, 2023
    Date of Patent: March 18, 2025
    Assignee: Codexis, Inc.
    Inventors: Jeffrey C. Moore, Jack Liang, Jonathan Penfield, Jovana Nazor, Nikki Dellas, Vesna Mitchell, Da Duan, Iman Farasat, Agustina Rodriguez-Granillo, Grant Murphy, Nicholas Marshall
  • Publication number: 20240068005
    Abstract: The present invention provides engineered ketoreductase and phosphite dehydrogenase enzymes having improved properties as compared to a naturally occurring wild-type ketoreductase and phosphite dehydrogenase enzymes, as well as polynucleotides encoding the engineered ketoreductase and phosphite dehydrogenase enzymes, host cells capable of expressing the engineered ketoreductase and phosphite dehydrogenase enzymes, and methods of using the engineered ketoreductase and phosphite dehydrogenase enzymes to synthesize a chiral catalyst used in the synthesis of antiviral compounds, such as nucleoside inhibitors. The present invention further provides methods of using the engineered enzymes to deracemize a chiral alcohol in a one-pot, multi-enzyme system.
    Type: Application
    Filed: July 14, 2023
    Publication date: February 29, 2024
    Inventors: Jeffrey C. Moore, Jack Liang, Jonathan Penfield, Jovana Nazor, Nikki Dellas, Vesna Mitchell, Da Duan, Iman Farasat, Agustina Rodriguez-Granillo, Grant Murphy, Nicholas Marshall
  • Patent number: 11746369
    Abstract: The present invention provides engineered ketoreductase and phosphite dehydrogenase enzymes having improved properties as compared to a naturally occurring wild-type ketoreductase and phosphite dehydrogenase enzymes, as well as polynucleotides encoding the engineered ketoreductase and phosphite dehydrogenase enzymes, host cells capable of expressing the engineered ketoreductase and phosphite dehydrogenase enzymes, and methods of using the engineered ketoreductase and phosphite dehydrogenase enzymes to synthesize a chiral catalyst used in the synthesis of antiviral compounds, such as nucleoside inhibitors. The present invention further provides methods of using the engineered enzymes to deracemize a chiral alcohol in a one-pot, multi-enzyme system.
    Type: Grant
    Filed: April 26, 2021
    Date of Patent: September 5, 2023
    Assignee: Codexis, Inc.
    Inventors: Jeffrey C. Moore, Jack Liang, Jonathan Penfield, Jovana Nazor, Nikki Dellas, Vesna Mitchell, Da Duan, Iman Farasat, Agustina Rodriguez-Granillo, Grant Murphy, Nicholas Marshall
  • Publication number: 20210254119
    Abstract: The present invention provides engineered ketoreductase and phosphite dehydrogenase enzymes having improved properties as compared to a naturally occurring wild-type ketoreductase and phosphite dehydrogenase enzymes, as well as polynucleotides encoding the engineered ketoreductase and phosphite dehydrogenase enzymes, host cells capable of expressing the engineered ketoreductase and phosphite dehydrogenase enzymes, and methods of using the engineered ketoreductase and phosphite dehydrogenase enzymes to synthesize a chiral catalyst used in the synthesis of antiviral compounds, such as nucleoside inhibitors. The present invention further provides methods of using the engineered enzymes to deracemize a chiral alcohol in a one-pot, multi-enzyme system.
    Type: Application
    Filed: April 26, 2021
    Publication date: August 19, 2021
    Inventors: Jeffrey C. Moore, Jack Liang, Jonathan Penfield, Jovana Nazor, Nikki Dellas, Vesna Mitchell, Da Duan, Iman Farasat, Agustina Rodriguez-Granillo, Grant Murphy, Nicholas Marshall
  • Patent number: 11021729
    Abstract: The present invention provides engineered ketoreductase and phosphite dehydrogenase enzymes having improved properties as compared to a naturally occurring wild-type ketoreductase and phosphite dehydrogenase enzymes, as well as polynucleotides encoding the engineered ketoreductase and phosphite dehydrogenase enzymes, host cells capable of expressing the engineered ketoreductase and phosphite dehydrogenase enzymes, and methods of using the engineered ketoreductase and phosphite dehydrogenase enzymes to synthesize a chiral catalyst used in the synthesis of antiviral compounds, such as nucleoside inhibitors. The present invention further provides methods of using the engineered enzymes to deracemize a chiral alcohol in a one-pot, multi-enzyme system.
    Type: Grant
    Filed: April 13, 2018
    Date of Patent: June 1, 2021
    Assignee: Codexis, Inc.
    Inventors: Jeffrey C. Moore, Jack Liang, Jonathan Penfield, Jovana Nazor, Nikki Dellas, Vesna Mitchell, Da Duan, Iman Farasat, Agustina Rodriguez-Granillo, Grant Murphy, Nicholas Marshall
  • Publication number: 20200123585
    Abstract: The present invention provides engineered ketoreductase and phosphite dehydrogenase enzymes having improved properties as compared to a naturally occurring wild-type ketoreductase and phosphite dehydrogenase enzymes, as well as polynucleotides encoding the engineered ketoreductase and phosphite dehydrogenase enzymes, host cells capable of expressing the engineered ketoreductase and phosphite dehydrogenase enzymes, and methods of using the engineered ketoreductase and phosphite dehydrogenase enzymes to synthesize a chiral catalyst used in the synthesis of antiviral compounds, such as nucleoside inhibitors. The present invention further provides methods of using the engineered enzymes to deracemize a chiral alcohol in a one-pot, multi-enzyme system.
    Type: Application
    Filed: April 13, 2018
    Publication date: April 23, 2020
    Inventors: Jeffrey C. Moore, Jack Liang, Jonathan Penfield, Jovana Nazor, Nikki Dellas, Vesna Mitchell, Da Duan, Iman Farasat, Agustina Rodriguez-Granillo, Grant Murphy, Nicholas Marshall